Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL628678 | 0.98 | NNMT (0.68) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| Acetone SCHEMBL17558521 | 0.94 | NNMT (0.69) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| SCHEMBL20518762 | 0.88 | NNMT (0.57) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| Succinimide SCHEMBL28645192 | 0.87 | NNMT (0.55) | NNMTSMN1; SMN2EPHX2GRM5 | |
| SCHEMBL8722229 | 0.84 | NNMT (0.50) | NNMTKDM4EHCAR3 | |
| SCHEMBL29505896 | 0.84 | HCAR3 (0.67) | HCAR3 | |
| SCHEMBL18715409 | 0.84 | NNMT (0.70) | NNMTSMN1; SMN2EPHX2GRM5KDM4E | |
| SCHEMBL158601 | 0.84 | HCAR3 (0.67) | HCAR3 | |
| Succinimide SCHEMBL28224691 | 0.83 | NNMT (0.55) | NNMTSMN1; SMN2EPHX2HCAR3 | |
| SCHEMBL8815728 | 0.82 | NNMT (0.49) | NNMTHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098617-A1 | RADIOPHARMACEUTICAL TARGETING CARBONIC ANHYDRASE IX PROTEIN | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | UNIV MUENCHEN TECH (DE) | 2026-01-22 | — | — | US | claimed |
| EP-4651910-A1 | DUAL LABELLED COMPOUNDS TARGETING THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2025-11-26 | — | — | EP | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| WO-2025202114-A1 | RADIOSENSITISING PEPTIDE COMPLEX | GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROPE (FR) | 2025-10-02 | — | — | WO | claimed |
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | BeijingGiluntidePharmaceuticalCo.,Ltd. (CN) | 2025-09-25 | — | — | US | claimed |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GMBH (NL) | 2025-09-23 | — | — | US | claimed |
| EP-2334814-A1 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE | Solulink Biosciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| CN-101851313-A | Technetium-99m-marked poly N-vinyl benzyl-D-lactose amide composition and preparation method | UNIV BEIJING NORMAL | 2010-10-06 | — | — | CN | claimed |
| US-20100216132-A1 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE | UNIVERSITY OF CHICAGO | 2010-08-26 | — | — | US | claimed |
| EP-1934251-B1 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | STICHTING KATHOLIEKE UNIV (NL) | 2010-06-16 | — | — | EP | claimed |
| WO-2010028388-A1 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE | SOLULINK BIOSCIENCES, INC. (US) | 2010-03-11 | — | — | WO | claimed |
| US-20080274050-A1 | Labelled Adrenomedullin Derivatives and Their Use for Imaging and Therapy | INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) | 2008-11-06 | — | — | US | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| US-20070243132-A1 | Transdermal delivery of pharmaceutical agents | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-10-18 | — | — | US | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| US-4141977-A | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | YU RUEY J | 1979-02-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | NNMT 3339/4885SMN1; SMN2 2283/4885EPHX2 2028/4885 |
| US-20250295821-A1 | TARGETED RADIOPHARMACEUTICAL FOR TUMOR AND ITS USE IN THE IMAGING-GUIDED COMBINATION THERAPY OF TARGETED RADIOTHERAPY AND IMMUNOTHERAPY | CD274, ITGB1, ITGA1 | NNMT 4793/4885SMN1; SMN2 4084/4885EPHX2 4650/4885 |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | HNRNPF, ANXA3, SLC67A1 | NNMT 4701/4885SMN1; SMN2 3950/4885EPHX2 900/4885 |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | FOLH1, SLC19A1, KLK3 | NNMT 3874/4885SMN1; SMN2 772/4885EPHX2 4326/4885 |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CD47, TFRC, L1CAM | NNMT 4344/4885SMN1; SMN2 460/4885EPHX2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.